Cardinal Health, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

AI-generated analysis

📈 Jim Cramer identifies Cardinal Health as an 'absolute favorite' due to its transition from a commoditized provider to a specialized player with higher-margin healthcare services.

💰 Fiscal Q4 revenue rose 6% to $63.7 billion, though it missed estimates, partially offset by a $0.31 per share tariff refund benefit.

🚀 Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, targeting $12.40 to $12.60 with adjusted free cash flow of $3.5 billion to $4 billion.

🏥 The 'Other' segment, including precision health and at-home solutions, is expected to deliver 11% to 13% revenue growth and 15% to 18% profit growth in fiscal 2027.

🤝 Cardinal agreed to acquire AdaptHealth's diabetes business and Strive Medical for approximately $360 million to expand at-home medical-supply operations.

⚠️ The stock has rerated close to record highs, creating valuation risk if specialty growth slows or drug-pricing pressures increase distributor fees.

📉 Customer concentration poses a vulnerability, with CVS Health accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%.

💸 Fiscal 2027 adjusted free cash flow projections of $3.5 billion to $4 billion are below the roughly $5 billion generated in fiscal 2026.

📉 Hedge fund ownership decreased slightly to 63 funds in Q2, down from 66 in Q1, while short interest remains low at around 2.7% to 2.8%.

🎯 Cramer believes Cardinal is a 'big winner' in high-interest-rate environments, provided management delivers on its credible earnings growth case.

Bullish Signals
  • Jim Cramer calls Cardinal Health an 'absolute favorite' due to its successful pivot from commoditized distribution to specialized healthcare services with higher margins.
  • The company is running circles around competitors like McKesson and Cencora by effectively converting pharmaceutical volume into earnings despite lower drug prices.
  • Fiscal Q4 revenue grew 6% to $63.7 billion, demonstrating resilience in a challenging pricing environment driven by Medicare negotiations.
  • Management projects robust fiscal 2027 non-GAAP EPS growth of 13% to 15%, signaling strong confidence in future profitability.
  • The high-margin 'Other' segment is expected to grow revenue by 11% to 13% and profits by 15% to 18% in fiscal 2027, diversifying the business model.
  • Strategic acquisitions of AdaptHealth's diabetes business and Strive Medical for $360 million will expand the company's at-home medical-supply footprint.
Risk Factors
  • The stock has rerated close to its record high, creating significant valuation risk if specialty growth slows or margins fall short of expectations.
  • Lower branded-drug prices and potential Medicare negotiation impacts can reduce reported sales without a proportional decline in distributor fees, pressuring margins.
  • Customer concentration is a major vulnerability, with CVS Health alone accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%.
  • Projected fiscal 2027 adjusted free cash flow of $3.5 billion to $4 billion is below the roughly $5 billion generated in fiscal 2026, raising concerns about cash generation quality.
Full Analysis
Jim Cramer highlighted Cardinal Health (CAH) as an 'absolute favorite' on Mad Money, citing its strategic shift from a commoditized distributor to a specialized player with growing exposure to higher-margin healthcare services and specialty pharmaceuticals. The company is outperforming peers like McKesson and Cencora by converting volume into earnings despite lower branded-drug prices driven by Medicare negotiations. Cardinal Health reported fiscal fourth-quarter revenue of $63.7 billion, a 6% increase that missed estimates but was offset by a $0.31 per share tariff refund benefit. Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, reaching $12.40 to $12.60, with adjusted free cash flow expected between $3.5 billion and $4 billion. The company is expanding its 'Other' segment, which includes precision health solutions and at-home services, targeting 11% to 13% revenue growth. Despite the bullish outlook, risks include execution challenges given the stock's rerating near record highs and a forward P/E of 19.01. The company faces potential margin pressure if drug-pricing changes reduce distributor fees or if specialty growth slows. Additionally, customer concentration remains a vulnerability, with CVS Health accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%, exposing earnings to contract losses. Institutional ownership shows 63 hedge funds holding CAH in the second quarter, down slightly from the first. Cramer argues that in a high-interest-rate environment, Cardinal's credible earnings growth case makes it too attractive to ignore, though investors will need management to deliver on promises after the substantial rerating.